We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Oxurion NV | EU:OXUR | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.0001 | 0.0001 | 0.0002 | 0.0001 | 0.0001 | 0.0001 | 290,000 | 08:00:07 |
From Mar 2024 to May 2024
Postponement Annual Shareholders Meeting - Amendment financial calendarLeuven, BELGIUM – April 5, 2024 – 02:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today made the following announcement regarding its financial calendar.
Due to administrative reasons, the annual accounts of the Company have not been finalized yet. Hence, the Company has decided to postpone its Annual Shareholders Meeting to Thursday May 16, 2024.
The financial calendar on the Company website has been updated accordingly.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.
Please contact for additional information:
| Oxurion NVPascal GhosonChief Executive Officerpascal.ghoson@oxurion.com | Backstage CommunicationJurgen VluijmansPartnerjurgen@backstagecom.be |
Attachments
1 Year Oxurion NV Chart |
1 Month Oxurion NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
